I50.1
Conditions
Interventions
Group 1: All Study subjects will undergo two consecutive MR examinations within the same day: 1) metabolic imaging using Hyperpolarized Pyruvate Injection (at 3.0T field strength)
2) functional and microstructural imaging (1.5T). Besides clinically established MR measurements of cardiac function and myocardial perfusion, the present study will assess microstructural and metabol
Sponsors
Institut für Biomedizinische Technik (IBT) der Universität und ETH Zürich
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age of 18 years or older; signed Informed Consent Form; previously diagnosed heart failure. In a first, preliminary part of the study (pilot study, N = 5), also adults without cardiac pathologies will be enrolled.
Exclusion criteria
Exclusion criteria: Medically unstable or acute conditions; severe claustrophobia; known or suspected allergy to Gadovist or other Gadolinium based contrast agents; moderate or worse renal insufficiency; atrioventricular block of higher degree; allergic asthma bronchiale; diabetes mellitus; implants contraindicated at 1.5T or 3.0T; pregnancy; lactation; other physical/mental/linguistic conditions incompatible with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| microstructural and metabolic changes of remodeling vs. remote myocardium in patients with heart failure (assessed by MR imaging) | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of myofiber stress and glycolytic metabolic activity in remodeling vs. remote myocardium in patients with heart failure. These markers precede changes of routine parameters including ventricular volumes, ejection fraction, septal thickness, and eccentricity. | — |
Countries
Switzerland
Contacts
Public ContactSebastian Kozerke
Institut für Biomedizinische Technik (IBT) der Universität und ETH Zürich
Outcome results
None listed